Entero Healthcare Solutions
1,062.70
+28.90(+2.80%)
Market Cap₹4,623.69 Cr
PE Ratio36.44
IndustryRetail
Company Performance:
1D+2.80%
1M-4.42%
6M-20.81%
1Y-21.04%
5Y-7.56%
View Company Insightsright
More news about Entero Healthcare Solutions
12Nov 25
Entero Healthcare Solutions Reports Strong Q2 Growth, Plans Strategic Acquisitions
Entero Healthcare Solutions posted robust Q2 FY25-26 results with a 33.90% increase in net profit to Rs 316.00 million and 20.80% revenue growth to Rs 15.71 billion. The company plans to acquire an 80% stake in Bioaide Technologies and a 51% stake in Anand Chemiceutics to expand its market reach and product portfolio in healthcare distribution. Abhitesh Kumar has been elevated to Chief Growth Officer to drive expansion plans.
29Sept 25
Entero Healthcare Solutions Reshapes Portfolio: Sells Suprabhat Pharmaceutical, Eyes Majority Stake in Ace Cardiopathy
Entero Healthcare Solutions has announced two major transactions. The company will divest its entire 100% stake in Suprabhat Pharmaceutical Private Limited for up to INR 37,00,000, to be completed in FY 2025-26. Simultaneously, Entero will acquire a 60% stake in Ace Cardiopathy Solutions Private Limited, a medical devices distributor, for INR 59.30-77.10 crore. The acquisition is expected to be finalized by January 31, 2026. These moves aim to streamline operations and expand Entero's presence in the medical devices distribution sector.
13Aug 25
GIC Private Limited Reduces Stake in Entero Healthcare Solutions to 3.14%
The Government of Singapore (GOS), through GIC, has sold 9,846 equity shares of Entero Healthcare Solutions Limited on August 11, 2025. This transaction reduced GIC's shareholding from 3.16% to 3.14% of the company's total share capital. GIC's stake has been gradually decreasing since February 2024, when it held a 5.16% stake. The disclosure was made in compliance with SEBI regulations.
08Aug 25
Entero Healthcare Solutions Reports Q1 Results, Extends Pharma Acquisition Deadline
Entero Healthcare Solutions Limited reported robust Q1 financial results with consolidated revenue reaching ₹14,038.19 million and net profit of ₹302.32 million. The company acquired a 70% stake in Ramson Medical Distributors and increased its shareholding in Peerless Biotech to 76%. The deadline for acquiring equity shares in four pharma companies has been extended to November 30. Three non-operating subsidiaries were struck off during the quarter.
27May 25
Entero Healthcare Solutions Reports Strong Q4 Performance with Significant EBITDA and Profit Growth
Entero Healthcare Solutions announced impressive Q4 financial results. EBITDA surged 69.20% to ₹489.00 crore, with EBITDA margin improving to 3.65%. Consolidated net profit increased 22.40% to ₹257.00 crore. Revenue grew 29.60% to ₹13,400.00 crore. The company's performance demonstrates operational efficiency and strong market position in the healthcare sector.
19Mar 25
Entero Healthcare Solutions Expands Digital Footprint with Aayu Chemist and Medcords Acquisition
Entero Healthcare Solutions has acquired the Aayu Chemist app and Medcords platform from Medcords Healthcare as part of its new 'HealthEdge' programme. This initiative aims to digitally empower retail chemists across India with features like inventory management, expiry management, online store management, and financial support. The acquisition is expected to strengthen Entero's market position, which currently serves over 86,200 retail pharmacies and 3,200 hospitals across 492 districts in India.
06Mar 25
Entero Healthcare Solutions Boosts Stake in Getwell Medicare with ₹170 Crore Investment
Entero Healthcare Solutions Limited has increased its stake in subsidiary Getwell Medicare Solutions Private Limited from 85% to 95.20% through a ₹170 crore investment in equity shares on a rights basis. This strategic move expands Entero's shareholding from 68,00,000 to 2,38,00,000 equity shares, strengthening its position in the healthcare sector.
Entero Healthcare Solutions
1,062.70
+28.90
(+2.80%)
1 Year Returns:-21.04%
Industry Peers
Vijaypd Ceutical
47.25
(-0.42%)
Trimurthi
60.01
(+4.99%)